Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation

Published:2014-08-20 Issue:4 Volume:29 Page:783-787
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Kamel S,Horton L,Ysebaert L,Levade M,Burbury K,Tan S,Cole-Sinclair M,Reynolds J,Filshie R,Schischka S,Khot A,Sandhu S,Keating M J,Nandurkar H,Tam C S

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2014247.pdf

Reference15 articles.

1. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum K et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32–42.

2. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371: 213–223.

3. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507–516.

4. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88–94.

5. Quek LS, Bolen J, Watson SP . A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol 1998; 8: 1137–1140.

Cited by 196 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Bruton’s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments;Advances in Rheumatology;2024-08-21

2. NF-kB affects migration of vascular smooth muscle cells after treatment with heparin and ibrutinib;Biochemistry and Biophysics Reports;2024-07

3. BTK inhibitors in CLL: second-generation drugs and beyond;Blood Advances;2024-05-14

4. Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia;JACC: CardioOncology;2023-10

5. Antiplatelet and Wound Healing Implications of Immunotherapy and Targeted Cancer Therapies in the Perioperative Period;Anesthesiology;2023-09-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3